Oligo-γ-Glutamic Acid Lipids for PEG-Free Nanoparticle Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid nanoparticles used in nucleic acid-based medicines, particularly PEGylated lipids, cause hypersensitivity reactions and immune responses, necessitating the development of alternatives that maintain stability and reduce side effects.
Innovation Solution
Development of novel lipid derivatives based on oligo-γ-glutamic acid to replace PEGylated lipids, forming lipid nanoparticles that enhance colloidal stability and reduce aggregation, thereby improving in vivo stability and minimizing allergic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PEGylated lipid is used in lipid nanoparticle formulation, then colloidal stability and in vivo stability are improved, but hypersensitivity reactions and immune responses occur
Solution Approach 1:
The patent changes the chemical structure parameter of the stabilizing lipid component by replacing PEGylated lipid with oligo-γ-glutamic acid-based lipid. This structural parameter change maintains the colloidal stability function while eliminating the harmful immune responses associated with PEG, thus resolving the contradiction between reliability and harmful factors.
Solution Approach 2:
The patent creates a composite lipid structure combining oligo-γ-glutamic acid with lipid moieties (fatty acid chains). This composite material approach preserves the stabilizing properties needed for in vivo performance while using biocompatible, non-immunogenic components to avoid hypersensitivity reactions.
2Stability of the object's composition
If PEGylated lipid is used in lipid nanoparticle formulation, then particle aggregation is reduced, but side effects such as allergic reactions increase
Solution Approach 1:
The patent modifies the chemical composition parameter by substituting PEGylated lipid with oligo-γ-glutamic acid-based lipid. This change maintains the colloidal stability required to prevent particle aggregation while eliminating the allergenic properties of PEG, thereby resolving the contradiction between composition stability and harmful side effects.
Solution Approach 2:
The patent employs oligo-γ-glutamic acid, a biodegradable and biocompatible material that is naturally metabolized in the body. This approach uses a transient, easily eliminated substance to provide temporary stabilization during delivery, avoiding the persistent immune activation caused by PEG.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are a novel lipid derivative compound including oligo-γ-glutamic acid, a lipid nanoparticle composition including the same, and the like. According to the present disclosure, the compound may form lipid nanoparticles by replacing PEGylated lipid, thereby preventing side effects such as anaphylaxis and exhibiting excellent in vivo stability.